Andrei Shustov
Chief Tech/Sci/R&D Officer chez CELLECTAR BIOSCIENCES, INC.
Fortune : 219 047 $ au 31/03/2024
Profil
Andrei Shustov is currently a Senior Vice President-Medical at Cellectar Biosciences, Inc. He previously worked as a Senior Medical Director-Late Stage Clinical at Seagen Inc. Shustov earned a doctorate degree from S.
I.
Georgievsky's Medical Academy in 1987.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/12/2023 | 55 037 ( 0,45% ) | 219 047 $ | 31/03/2024 |
Postes actifs de Andrei Shustov
| Sociétés | Poste | Début |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 15/02/2023 |
Anciens postes connus de Andrei Shustov
| Sociétés | Poste | Fin |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | - |
Formation de Andrei Shustov
| S. I. Georgievsky's Medical Academy | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
